Altitude sickness represents the most serious acute health risk on the Salkantay Trek. Yet it remains inadequately understood by most trekkers. Common misconceptions include the belief that altitude sickness reflects poor fitness (it doesn’t), that it’s inevitable (it isn’t), and that pushing through symptoms proves effective (it’s dangerous).
The reality is more nuanced: altitude sickness exists on a spectrum ranging from mild self-limited symptoms to life-threatening emergencies. Understanding this spectrum, recognizing early warning signs, distinguishing benign acclimatization symptoms from pathological altitude sickness, and knowing when descent becomes necessary are critical knowledge domains for safe trekking.
This comprehensive guide explores the physiological basis of altitude sickness, provides detailed symptom recognition frameworks, explains the pathophysiology of severe altitude sickness, and outlines decision trees for determining when descent is necessary. For trekkers preparing for the Salkantay, this medical knowledge often determines the difference between a challenging-but-successful experience and a dangerous situation requiring evacuation.
Altitude exposure triggers responses ranging from completely benign to life-threatening. Understanding this spectrum allows appropriate interpretation of symptoms.
First, it’s essential to recognize that certain altitude responses are completely normal and benign:
Mild Dyspnea: Increased breathing even at rest is normal and expected. This hyperventilation reflects the appropriate physiological response to hypoxia.
Mild Headache: Light headache, often described as pressure in the frontal or temporal regions, occurs in 30-40% of trekkers during initial altitude exposure. This typically resolves within 24-48 hours without intervention.
Mild Insomnia and Vivid Dreams: Sleep disruption at altitude is expected, as detailed in previous articles. This doesn’t indicate altitude sickness.
Mild Fatigue: Feeling tired at altitude is normal. Increased rest needs reflect the metabolic demands of altitude exposure.
Decreased Appetite: Appetite reduction at altitude is physiologically normal, not pathological.
Occasional Dizziness: Mild transient dizziness, particularly upon standing, reflects blood pressure regulation adjustments and is benign.
The critical distinction: these symptoms are expected, they improve with time and descent, and their presence doesn’t necessarily indicate altitude sickness requiring intervention.
Acute Mountain Sickness (AMS) represents the mildest clinically-significant altitude sickness. It involves the development of characteristic symptoms in the context of altitude exposure.
Lake Louise Scoring System for AMS Diagnosis:
The standard clinical tool for AMS assessment involves the Lake Louise Score, which evaluates four symptoms:
Headache (0-3 points):
Gastrointestinal Symptoms (0-3 points):
Fatigue/Weakness (0-3 points):
Dizziness/Lightheadedness (0-3 points):
Total Score Interpretation:
Important Distinction: AMS requires the presence of headache PLUS at least one other symptom. A single symptom, even if severe, doesn’t constitute AMS.
High Altitude Cerebral Edema represents a life-threatening complication where brain tissue swelling (cerebral edema) occurs in response to altitude exposure.
Physiological Mechanism:
Under severe hypoxia, the blood-brain barrier becomes compromised. Normally, this barrier tightly controls what substances enter brain tissue. At extreme altitudes or with severe altitude exposure, this barrier function deteriorates, allowing fluid to accumulate in brain tissue.
Additionally, hypoxia triggers vasodilation (blood vessel widening) in the brain, increasing intracranial pressure. Fluid accumulation and pressure increase combine to create progressive brain swelling—cerebral edema.
Warning Symptoms of HACE (in order of typical appearance):
Inability to perform these tasks, particularly when previously capable, indicates ataxia.
Critical Recognition: HACE is a medical emergency. Immediate descent is mandatory. Descent of 1,000+ meters typically produces rapid improvement within hours.
High Altitude Pulmonary Edema involves fluid accumulation in the lungs—a condition impairing oxygen exchange and proving life-threatening if untreated.
Physiological Mechanism:
At altitude, the pulmonary circulation (blood vessels in the lungs) experiences hypoxic vasoconstriction—blood vessels narrow in response to low oxygen. This narrowing increases pressure in the pulmonary circulation. Additionally, some individuals show exaggerated pulmonary vascular responses to hypoxia.
Elevated pulmonary pressure forces fluid from blood vessels into lung tissue and alveoli (air sacs). This fluid accumulation impairs oxygen exchange, worsening hypoxemia—a positive feedback loop where low oxygen causes swelling that further reduces oxygen exchange.
Risk Factors for HAPE:
Warning Symptoms of HAPE:
Critical Recognition: HAPE is a medical emergency. Descent is mandatory. Oxygen supplementation, if available, helps while descent is arranged.
A critical skill for trekkers involves distinguishing benign altitude responses from pathological AMS requiring intervention.
Normal Responses: Improve within 24-48 hours as acclimatization proceeds.
AMS: Either stabilizes at a constant severity level or worsens. AMS that doesn’t improve within 24 hours at the same elevation warrants descent.
Normal Responses: Typically mild and improve progressively.
AMS: May intensify on day 2-3 despite remaining at the same elevation (the “third-day phenomenon” mentioned in earlier articles), due to cumulative fatigue and other factors.
Normal Responses:
AMS:
Normal Responses: Trekkers continue hiking at normal pace, complete daily distance comfortably.
AMS: Hiking becomes substantially more difficult. Normal pace becomes unachievable. Trekkers fall significantly behind the group pace.
While altitude sickness affects individuals relatively indiscriminately (fitness doesn’t predict AMS incidence), certain factors increase risk.
The single strongest predictor of AMS incidence is how quickly elevation increases.
Rapid ascent (gaining more than 500 meters daily above 2,500 meters) dramatically increases AMS risk. Slow ascent (gaining less than 300 meters daily above 2,500 meters) reduces AMS incidence substantially.
The Salkantay Trek’s rapid ascent profile (gaining 1,200+ meters on day 1, reaching 4,650 meters by day 2) creates inherently higher AMS risk compared to slower-paced treks.
Individuals with previous altitude sickness episodes show 50-75% recurrence risk at comparable elevations. This predictive power is stronger than any other personal factor.
Surprisingly, age shows minimal relationship to AMS incidence. Young and old individuals experience comparable AMS rates.
Sex shows modest effects: pre-menstrual women show slightly elevated AMS risk, while post-menopausal women show slightly lower risk. However, these differences are modest and don’t substantially alter individual prediction.
Cardiopulmonary fitness shows surprisingly weak correlation with AMS. Elite athletes experience AMS at rates comparable to sedentary individuals at equivalent elevations.
This occurs because AMS reflects hypoxia response, not exercise capacity. Fit individuals can exercise harder at altitude but don’t inherently acclimatize faster.
The degree to which an individual’s breathing increases in response to hypoxia varies considerably. Individuals with robust HVR (strong breathing response to low oxygen) tend to acclimatize faster and experience less AMS.
HVR is largely genetically determined and can’t be substantially modified through training. However, it explains why some individuals from sea level suffer severe AMS while others experience minimal symptoms.
Dehydration amplifies AMS symptoms substantially. Maintaining hydration reduces AMS incidence by approximately 30% in research studies.
The most effective AMS prevention strategy is slow ascent—limiting elevation gain to 300-500 meters daily above 2,500 meters. This allows acclimatization processes to proceed without overwhelming physiological capacity.
The Salkantay Trek’s rapid ascent profile means slow-ascent prevention isn’t fully achievable. However, alternative strategies partially compensate.
Acetazolamide, a carbonic anhydrase inhibitor, accelerates acclimatization by chemically mimicking acclimatization processes. Research demonstrates approximately 50% AMS reduction with acetazolamide use.
Dosing: 125-250mg twice daily, beginning 24 hours before altitude exposure.
Mechanism: Acetazolamide increases bicarbonate excretion and reduces blood pH, increasing respiratory drive and improving oxygenation.
Side Effects: Tingling sensations in fingers, lips, and toes (paresthesias) occur in 50-75% of users. These are harmless but noticeable. Some experience altered taste perception.
Contraindications:
Efficacy on Salkantay: For the Salkantay’s rapid ascent profile, acetazolamide provides meaningful AMS reduction. Many trekkers benefit, though not universally.
Maintaining hydration status reduces AMS incidence measurably. The previously-outlined 3.5-4.5 liter daily intake supports both acclimatization and AMS reduction.
Alcohol impairs acclimatization and increases AMS risk. Avoiding alcohol for the first 48 hours at altitude reduces AMS incidence.
Sedative medications depress respiratory drive, impairing acclimatization. Avoiding sedatives during initial altitude exposure proves beneficial.
Light to moderate exercise on arrival days facilitates acclimatization more than complete rest. However, vigorous exercise, while often desired by fit individuals, actually impairs early acclimatization.
The optimal approach: moderate activity (easy hiking at relaxed pace) on arrival days, avoiding intense exertion.
For mild AMS (Lake Louise Score 3-5):
Rest: Take a full rest day at current elevation. Most mild AMS resolves within 24 hours with rest.
Hydration: Increase fluid intake to 4-5 liters daily.
Nutrition: Ensure adequate caloric and carbohydrate intake, despite appetite reduction.
Analgesia: Ibuprofen (400mg three times daily) or acetaminophen (650mg three times daily) addresses headache and body aches.
Ginger: Ginger supplements or tea (1-2 grams daily) may reduce nausea.
Acetazolamide: If symptoms persist beyond 24 hours despite rest, starting acetazolamide (125-250mg twice daily) often produces improvement within 12-24 hours.
Descent: If symptoms worsen despite treatment or don’t improve within 24 hours, descend 500+ meters. Descent is the definitive AMS treatment.
For moderate AMS (Lake Louise Score 6-8):
Immediate Descent: Descend at least 500 meters (1,000 meters is safer). Plan descent for that day rather than waiting.
Acetazolamide: If descent will be delayed, start acetazolamide (125-250mg twice daily).
Oxygen: If available (which is unusual on the Salkantay Trek), supplemental oxygen reduces symptoms and accelerates improvement.
Supportive Care: Rest, hydration, nutrition as for mild AMS.
Prevention of Progression: The critical concern with moderate AMS is progression to HACE. Close monitoring for ataxia, altered consciousness, or worsening symptoms is mandatory.
For severe AMS (Lake Louise Score > 8), HACE, or HAPE:
Immediate Descent: Descend immediately, regardless of time of day or weather. Even partial descent (500-1000m) provides benefit.
Oxygen: If available, high-flow oxygen (if tolerated).
Medications:
Evacuation: Arrange evacuation to lower elevation immediately. Emergency helicopter evacuation may be necessary if descent is impossible.
Critical Point: Severe AMS, HACE, and HAPE are medical emergencies. Descent is non-negotiable. Attempting to push through or acclimatize to these conditions is dangerous.
A critical trekking skill involves deciding when symptoms warrant descent.
Question 1: Do you have AMS symptoms (headache plus at least one other symptom)?
If No: Continue normal trekking. Monitor for symptom development.
If Yes: Proceed to Question 2.
Question 2: Are symptoms mild (Lake Louise Score < 5)?
If Yes: Rest at current elevation for 24 hours. Reassess after 24 hours.
If No (moderate or severe): Proceed to Question 3.
Question 3: Do you have ANY signs of HACE (ataxia, confusion, or severe headache unresponsive to analgesia)?
If Yes: Descend immediately. This is a medical emergency.
If No: Proceed to Question 4.
Question 4: Do you have ANY signs of HAPE (worsening dyspnea, cough with frothy sputum, or rapid resting respiratory rate)?
If Yes: Descend immediately. This is a medical emergency.
If No: Proceed to Question 5.
Question 5: Are symptoms moderate (Lake Louise Score 6-8) without HACE/HAPE signs?
If Yes: Descend 500-1000 meters today. Continue descent until symptoms improve substantially.
If No: Continue normal trekking with close monitoring.
Beyond subjective symptom scoring, certain objective assessments indicate altitude sickness severity:
Ataxia Testing: The tandem stance test (standing heel-to-toe) takes 20 seconds. Inability to maintain stance indicates ataxia, a HACE warning sign warranting immediate descent.
Resting Heart Rate: Elevated resting heart rate (exceeding 120-140 bpm at rest) combined with other symptoms suggests physiological stress warranting descent.
Resting Respiratory Rate: Resting respiratory rate exceeding 30-35 breaths per minute combined with dyspnea suggests HAPE, warranting descent.
Oxygen Saturation: If a pulse oximeter is available, SpO2 < 75% at rest indicates significant hypoxemia; values < 70% suggest HAPE or severe AMS.
When descent becomes necessary, executing it safely matters.
Descend at a pace the affected individual can sustain. Rapid descent increases fall risk and injury. A steady pace of 300-500 meters per hour descent rate is reasonable.
If the affected individual can’t walk reliably (severe ataxia or confusion), other group members must provide support or arrange for assistance.
For mild-moderate AMS: Descend 500-1000 meters total.
For HACE or HAPE: Descend 1000+ meters. Multiple-day descents may be necessary depending on initial elevation and symptom severity.
After descending, rest at the lower elevation for 24+ hours. Re-ascent should proceed very slowly (300 meters per day) after symptoms resolve.
Important: Descending doesn’t grant immunity to re-ascent altitude sickness. Returning to prior elevations too quickly can retrigger symptoms.
Pre-menstrual women show slightly elevated AMS risk. Some evidence suggests that oral contraceptives (which stabilize hormonal fluctuations) reduce AMS incidence. This remains individual; consultation with a healthcare provider is recommended.
Hypertension: Individuals with hypertension should ensure medication optimization before the trek. Altitude may require medication adjustments.
Diabetes: Altitude changes insulin requirements. Blood glucose monitoring becomes essential. Coordination with healthcare providers is critical.
Cardiovascular Disease: Individuals with significant cardiac disease should consult cardiologists about altitude trekking safety. Generally, individuals with controlled cardiac conditions can trek at moderate elevations, but individual assessment is necessary.
Asthma: Altitude and cold-induced asthma can trigger exacerbations. Ensure asthma inhalers are available and bring extras.
Pregnancy increases altitude sickness risk. Additionally, altitude involves risks to fetal development. Generally, pregnancy combined with high-altitude trekking is inadvisable. Medical consultation is essential.
Most commercial Salkantay treks don’t carry prescription medications like acetazolamide, dexamethasone, or nifedipine. Trekkers should:
For standard pain relief, herbal remedies, and electrolyte supplements, most guide companies carry some options. Discuss medical kit contents with your trek operator during planning.
Serious altitude sickness (HACE or HAPE) may require evacuation—potentially by helicopter.
Critical Considerations:
Altitude sickness, while potentially serious, is a manageable risk with proper knowledge and preparation.
Understanding the spectrum from benign altitude responses to life-threatening HACE/HAPE allows appropriate symptom interpretation. Knowing prevention strategies—acetazolamide, slow ascent, hydration—reduces risk substantially. Recognizing warning signs and understanding when descent becomes necessary prevents progression to emergencies.
For Salkantay trekkers, this medical knowledge transforms altitude sickness from a mysterious and frightening possibility into a comprehensible physiological phenomenon with clear management protocols. Trekkers armed with this understanding make safer decisions, recognize problems earlier, and respond appropriately when intervention becomes necessary.
Most Salkantay trekkers experience only mild symptoms or no altitude sickness. However, the minority who develop moderate to severe symptoms benefit enormously from understanding that descent provides rapid recovery, that symptoms don’t represent personal weakness or failure, and that medical emergencies resulting from altitude sickness are preventable through informed decision-making.
